Tanaka, Ryo
Yamagishi, Yoji
Koiwai, Tomomi
Kono, Takako
Fukumura-Koga, Makiko
Einama, Takahiro
Yamasaki, Tamio
Sato, Kimiya
Ueno, Hideki
Kishi, Yoji
Tsuda, Hitoshi
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP 18K07340)
Article History
Received: 25 February 2020
Accepted: 20 May 2020
First Online: 3 June 2020
Compliance with ethical standards
:
: Dr. Einama reports personal fees from Eisai Co., outside the submitted work; Dr. Yamasaki reports Grants from Japan Society for the Promotion of Science, Novartis Pharma K.K., and Eisai Co., personal fees from Astrazeneca Co., Bristol-Meyers Squibb Co., Eisai Co., outside the submitted work; Dr. Kishi reports grants from Taiho Pharmaceutical Co., LTD, Japan Agency for Medical Research and Development, Eisai Co., LTD, Yakult Co., LTD, and Pfizer Co., LTD, personal fees from Yakult Co., LTD, Pfizer Co., LTD, Daiichi-Sankyo Co., LTD, Mylan Co., LTD, and Astrazeneca Co., LTD, outside the submitted work; Dr. Tsuda reports grants from Chugai Pharmaceutical Co., and Taiho Pharmaceutical Co., personal fees from Roche Diagnostics Co., from Konica Minolta Co., from Eisai Co., from Astrazeneca Co., and Bristol-Meyers Squibb Co., outside the submitted work. The other authors declare that they have no competing interests.
: The study was approved by the institutional review board of National Defense Medical College.
: All patients agreed to participate in this study, and a written informed consent was obtained from all patients.